Karolina Gaebe
Research Subjects
Karolina Gaebe has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Sunit Das
University of Toronto
4 shared publications - Alyssa Y. Li
Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine, The Hospital for Sick Children University of Toronto Toronto Ontario Canada
3 shared publications Anders W. Erickson
Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsKelvin K.W. Chan
Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsAdrian L. James
Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine, The Hospital for Sick Children University of Toronto Toronto Ontario Canada
1 shared publication- Allan D. Vescan
Department of Otolaryngology–Head and Neck Surgery, Faculty of Medicine, Mount Sinai Hospital University of Toronto Toronto Ontario Canada
1 shared publication
Latest Publications
- 22 July 2026
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review
Background: Extracellular vesicle (EV)-based therapies have emerged as a novel modality in aesthetic medicine due to their proposed ability to modulate inflammation, stimulate collagen synthesis, and promote tissue regeneration. Objectives: To systematically evaluate the effectiveness and safety of EV-based interventions for nonsurgical facial rejuvenation in adult patients. Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-adherent systematic review was conducted using MEDLINE, EMBASE, CENTRAL, Web of Science, and ClinicalTrials.gov (January 2000–June 2025). Eligible studies investigated EV therapies for facial rejuvenation outcomes. Risk of bias and methodological quality were assessed using tools appropriate to the study design. Certainty of evidence was evaluated using GRADE. Due to substantial heterogeneity, results were synthesized narratively. Results: Sixteen studies encompassing 503 participants were included, comprising split-face studies, comparative trials, and single-arm studies. Most studies reported improvement in at least one skin quality outcome, including wrinkle severity, pigmentation, hydration, elasticity, or overall appearance. Comparative studies generally favored EV-treated areas. No serious adverse events were reported. Risk of bias was moderate to critical for most effectiveness outcomes. GRADE certainty was low or very low. Conclusions: EV-based therapies demonstrate preliminary signals of benefit and short-term safety for facial rejuvenation. However, methodological limitations, inconsistent outcome assessment, and short follow-up preclude definitive conclusions.
- 22 July 2026
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review
Background: Extracellular vesicle (EV)-based therapies have emerged as a novel modality in aesthetic medicine due to their proposed ability to modulate inflammation, stimulate collagen synthesis, and promote tissue regeneration. Objectives: To systematically evaluate the effectiveness and safety of EV-based interventions for nonsurgical facial rejuvenation in adult patients. Methods: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-adherent systematic review was conducted using MEDLINE, EMBASE, CENTRAL, Web of Science, and ClinicalTrials.gov (January 2000–June 2025). Eligible studies investigated EV therapies for facial rejuvenation outcomes. Risk of bias and methodological quality were assessed using tools appropriate to the study design. Certainty of evidence was evaluated using GRADE. Due to substantial heterogeneity, results were synthesized narratively. Results: Sixteen studies encompassing 503 participants were included, comprising split-face studies, comparative trials, and single-arm studies. Most studies reported improvement in at least one skin quality outcome, including wrinkle severity, pigmentation, hydration, elasticity, or overall appearance. Comparative studies generally favored EV-treated areas. No serious adverse events were reported. Risk of bias was moderate to critical for most effectiveness outcomes. GRADE certainty was low or very low. Conclusions: EV-based therapies demonstrate preliminary signals of benefit and short-term safety for facial rejuvenation. However, methodological limitations, inconsistent outcome assessment, and short follow-up preclude definitive conclusions.
- Open Access
- 1 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0325803
Evaluation of large language models as a diagnostic tool for medical learners and clinicians using advanced prompting techniques
Background: Large language models (LLMs) have demonstrated capabilities in natural language processing and critical reasoning. Studies investigating their potential use as healthcare diagnostic tools have largely relied on proprietary models like ChatGPT and have not explored the application of advanced prompt engineering techniques. This study aims to evaluate the diagnostic accuracy of three open-source LLMs and the role of prompt engineering using clinical scenarios. Methods: We analyzed the performance of three open-source LLMs—llama-3.1-70b-versatile, llama-3.1-8b-instant, and mixtral-8x7b-32768—using advanced prompt engineering when answering Medscape Clinical Challenge questions. Responses were recorded and evaluated for correctness, accuracy, precision, specificity, and sensitivity. A sensitivity analysis was conducted presenting the three LLMs with basic prompting challenge questions and excluding cases with visual assets. Results were compared with previously published performance data on GPT-3.5. Results: Llama-3.1-70b-versatile, llama-3.1-8b-instant, and mixtral-8x7b-32768 achieved correct responses in 79%, 65%, and 62% of cases, respectively, outperforming GPT-3.5 (74%). Diagnostic accuracy, precision, sensitivity, and specificity responses all outperformed those previously reported for GPT-3.5. Results generated using advanced prompting strategies were superior to those based on basic prompting. Sensitivity analysis revealed similar trends when cases with visual assets were excluded. Discussion: Using advanced prompting techniques, LLMs can generate clinically accurate responses. The study highlights the limitations of proprietary models like ChatGPT, particularly in terms of accessibility and reproducibility due to version deprecation. Future research should employ prompt engineering techniques and prioritize the use of open-source models to ensure research replicability.
- 1 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0325803
Open AccessEvaluation of large language models as a diagnostic tool for medical learners and clinicians using advanced prompting techniques
Background: Large language models (LLMs) have demonstrated capabilities in natural language processing and critical reasoning. Studies investigating their potential use as healthcare diagnostic tools have largely relied on proprietary models like ChatGPT and have not explored the application of advanced prompt engineering techniques. This study aims to evaluate the diagnostic accuracy of three open-source LLMs and the role of prompt engineering using clinical scenarios. Methods: We analyzed the performance of three open-source LLMs—llama-3.1-70b-versatile, llama-3.1-8b-instant, and mixtral-8x7b-32768—using advanced prompt engineering when answering Medscape Clinical Challenge questions. Responses were recorded and evaluated for correctness, accuracy, precision, specificity, and sensitivity. A sensitivity analysis was conducted presenting the three LLMs with basic prompting challenge questions and excluding cases with visual assets. Results were compared with previously published performance data on GPT-3.5. Results: Llama-3.1-70b-versatile, llama-3.1-8b-instant, and mixtral-8x7b-32768 achieved correct responses in 79%, 65%, and 62% of cases, respectively, outperforming GPT-3.5 (74%). Diagnostic accuracy, precision, sensitivity, and specificity responses all outperformed those previously reported for GPT-3.5. Results generated using advanced prompting strategies were superior to those based on basic prompting. Sensitivity analysis revealed similar trends when cases with visual assets were excluded. Discussion: Using advanced prompting techniques, LLMs can generate clinically accurate responses. The study highlights the limitations of proprietary models like ChatGPT, particularly in terms of accessibility and reproducibility due to version deprecation. Future research should employ prompt engineering techniques and prioritize the use of open-source models to ensure research replicability.
- Open Access
- 12 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3877-3884
Cost Benefit and Carbon Emission Saving Analysis of Remote Cochlear Implant Programming
Objective: To assess the financial benefits and carbon emission savings associated with performing virtual‐synchronous remote programming and troubleshooting following cochlear implant (CI) placement for patients who live in remote regions.Methods: CI users living ≥ 100 km from the implant center with ≥ 1 month CI experience were included. Participants were either assigned to home visits using a portable laptop (Remote Laptop; n = 20) or attended visits through the nearest Remote Hosted Site (n = 34). Direct costs in Canadian dollars from a Ministry of Health perspective and carbon emissions were compared between remote and in‐person appointments at the implant center.Results: Median distances between participants' homes to the implant center were 574 km (Remote Laptop) and 999 km (Remote Hosted Site). Average costs for both groups of remote care were lower compared with in‐person appointments at the implant center (Remote Laptop: $180.70 vs. $431.61, p = 0.002; Remote Hosted Site: $155.34 vs. $1110.89, p < 0.001). Total cost reductions were $5018.23 and $32,488.76 with cost‐to‐benefit ratios of 2.39 and 7.15 for Remote Laptop and Remote Hosted Site groups, respectively. Net carbon emission benefits were 2200.00 kg and 5691.50 kg with net carbon benefit ratios of 512.63 and 5.25 for Remote Laptop and Remote Hosted Site, respectively.Conclusion: Virtual synchronous remote CI programming and troubleshooting generates cost savings in post‐surgical care. Additionally, it achieves remarkable carbon emissions savings. More widespread adoption is expected, especially for those who reside far from implant centers.
- 12 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3877-3884
Open AccessCost Benefit and Carbon Emission Saving Analysis of Remote Cochlear Implant Programming
Objective: To assess the financial benefits and carbon emission savings associated with performing virtual‐synchronous remote programming and troubleshooting following cochlear implant (CI) placement for patients who live in remote regions.Methods: CI users living ≥ 100 km from the implant center with ≥ 1 month CI experience were included. Participants were either assigned to home visits using a portable laptop (Remote Laptop; n = 20) or attended visits through the nearest Remote Hosted Site (n = 34). Direct costs in Canadian dollars from a Ministry of Health perspective and carbon emissions were compared between remote and in‐person appointments at the implant center.Results: Median distances between participants' homes to the implant center were 574 km (Remote Laptop) and 999 km (Remote Hosted Site). Average costs for both groups of remote care were lower compared with in‐person appointments at the implant center (Remote Laptop: $180.70 vs. $431.61, p = 0.002; Remote Hosted Site: $155.34 vs. $1110.89, p < 0.001). Total cost reductions were $5018.23 and $32,488.76 with cost‐to‐benefit ratios of 2.39 and 7.15 for Remote Laptop and Remote Hosted Site groups, respectively. Net carbon emission benefits were 2200.00 kg and 5691.50 kg with net carbon benefit ratios of 512.63 and 5.25 for Remote Laptop and Remote Hosted Site, respectively.Conclusion: Virtual synchronous remote CI programming and troubleshooting generates cost savings in post‐surgical care. Additionally, it achieves remarkable carbon emissions savings. More widespread adoption is expected, especially for those who reside far from implant centers.
- Open Access
- 2 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1563-1570
Delayed Postoperative Radiotherapy in Head & Neck Cancers—A Systematic Review and Meta‐Analysis
Objectives: To evaluate the impact of delayed postoperative radiotherapy (PORT) on overall survival (OS) in patients with head and neck cancers (HNC). Data Sources: A systematic review and meta‐analysis were conducted by searching MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL databases. Review Methods: Studies assessing the impact of delayed PORT in adult HNC patients were included. A total of 11,171 titles and abstracts were screened, with 52 studies meeting the inclusion criteria. Data were extracted, and a pooled random‐effects analysis was performed. The primary outcome was overall survival (OS), comparing patients receiving timely PORT (within 42 days) to those with delays. Results: Of the included studies, 31 were conducted in the United States, with 16 using the National Cancer Database (NCDB). Patients who did not receive PORT within 42 days had a 4% increase in mortality (adjusted Hazard Ratio [aHR]: 1.04 [1.03–1.06]; I 2 = 78%; N = 254,189; 16 studies). Excluding time‐overlapping NCDB‐based studies, the OS benefit for timely treatment persisted (aHR: 1.10 [1.01–1.20]; I 2 = 39%; N = 52,003; 5 studies). Conclusions: Initiating PORT within 42 days is significantly associated with decreased mortality in HNC patients, reinforcing CoC recommendations. However, more research is needed to understand the relationship between different time cutoffs and outcomes, and to identify factors contributing to PORT delays. Future studies should explore the impact of treatment delays on patient‐centered outcomes, such as Quality of Life (QoL). Level of Evidence: NA Laryngoscope , 135:1563–1570, 2025
- 2 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1563-1570
Open AccessDelayed Postoperative Radiotherapy in Head & Neck Cancers—A Systematic Review and Meta‐Analysis
Objectives: To evaluate the impact of delayed postoperative radiotherapy (PORT) on overall survival (OS) in patients with head and neck cancers (HNC). Data Sources: A systematic review and meta‐analysis were conducted by searching MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL databases. Review Methods: Studies assessing the impact of delayed PORT in adult HNC patients were included. A total of 11,171 titles and abstracts were screened, with 52 studies meeting the inclusion criteria. Data were extracted, and a pooled random‐effects analysis was performed. The primary outcome was overall survival (OS), comparing patients receiving timely PORT (within 42 days) to those with delays. Results: Of the included studies, 31 were conducted in the United States, with 16 using the National Cancer Database (NCDB). Patients who did not receive PORT within 42 days had a 4% increase in mortality (adjusted Hazard Ratio [aHR]: 1.04 [1.03–1.06]; I 2 = 78%; N = 254,189; 16 studies). Excluding time‐overlapping NCDB‐based studies, the OS benefit for timely treatment persisted (aHR: 1.10 [1.01–1.20]; I 2 = 39%; N = 52,003; 5 studies). Conclusions: Initiating PORT within 42 days is significantly associated with decreased mortality in HNC patients, reinforcing CoC recommendations. However, more research is needed to understand the relationship between different time cutoffs and outcomes, and to identify factors contributing to PORT delays. Future studies should explore the impact of treatment delays on patient‐centered outcomes, such as Quality of Life (QoL). Level of Evidence: NA Laryngoscope , 135:1563–1570, 2025
- Open Access
- 3 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102871
Brain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study
- 3 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102871
Open AccessBrain metastasis burden and management in patients with small cell lung cancer in Canada: a retrospective, population-based cohort study
- Open Access
- 17 March 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (1) , 23-34
Endoscopic Transnasal Management of Meningoceles and Encephaloceles in Children: A Systematic Review
Objective: To review surgical techniques used in the endoscopic transnasal repair of pediatric basal meningoencephaloceles and compare perioperative outcomes in children P = 0.004). Children P = 0.02), meningoencephalocele recurrence (P < 0.0001), and surgical reintervention (P = 0.005). Following multilayer repair, children P = 0.0001) and reintervention (P = 0.006).Conclusion: Younger children with basal meningoencephaloceles appear to be at greater risk of postoperative complications following endoscopic endonasal repair, although the quality of available evidence is weakened by incomplete reporting. In the absence of preoperative cerebrospinal fluid leak or meningitis, it may be preferable to delay surgery as access is more conducive to successful repair in older children.
- 17 March 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (1) , 23-34
Open AccessEndoscopic Transnasal Management of Meningoceles and Encephaloceles in Children: A Systematic Review
Objective: To review surgical techniques used in the endoscopic transnasal repair of pediatric basal meningoencephaloceles and compare perioperative outcomes in children P = 0.004). Children P = 0.02), meningoencephalocele recurrence (P < 0.0001), and surgical reintervention (P = 0.005). Following multilayer repair, children P = 0.0001) and reintervention (P = 0.006).Conclusion: Younger children with basal meningoencephaloceles appear to be at greater risk of postoperative complications following endoscopic endonasal repair, although the quality of available evidence is weakened by incomplete reporting. In the absence of preoperative cerebrospinal fluid leak or meningitis, it may be preferable to delay surgery as access is more conducive to successful repair in older children.
- Open Access
- 2 January 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102396
Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis
- 2 January 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102396
Open AccessRe-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis
- 11 November 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (7) , S28
Relationship Between Diet Intake and Quality With Renal Markers of Diabetic Nephropathy in Young Adults With Type 1 Diabetes
- 11 November 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (7) , S28
Relationship Between Diet Intake and Quality With Renal Markers of Diabetic Nephropathy in Young Adults With Type 1 Diabetes
- Open Access
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 855182
Intracranial Metastatic Disease: Present Challenges, Future Opportunities
Intracranial metastatic disease (IMD) is a prevalent complication of cancer that significantly limits patient survival and quality of life. Over the past half-century, our understanding of the epidemiology and pathogenesis of IMD has improved and enabled the development of surveillance and treatment algorithms based on prognostic factors and tumor biomolecular characteristics. In addition to advances in surgical resection and radiation therapy, the treatment of IMD has evolved to include monoclonal antibodies and small molecule antagonists of tumor-promoting proteins or endogenous immune checkpoint inhibitors. Moreover, improvements in the sensitivity and specificity of imaging as well as the development of new serological assays to detect brain metastases promise to revolutionize IMD diagnosis. In this review, we will explore current treatment principles in patients with IMD, including the emerging role of targeted and immunotherapy in select primary cancers, and discuss potential areas for further investigation.
- 7 March 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 855182
Open AccessIntracranial Metastatic Disease: Present Challenges, Future Opportunities
Intracranial metastatic disease (IMD) is a prevalent complication of cancer that significantly limits patient survival and quality of life. Over the past half-century, our understanding of the epidemiology and pathogenesis of IMD has improved and enabled the development of surveillance and treatment algorithms based on prognostic factors and tumor biomolecular characteristics. In addition to advances in surgical resection and radiation therapy, the treatment of IMD has evolved to include monoclonal antibodies and small molecule antagonists of tumor-promoting proteins or endogenous immune checkpoint inhibitors. Moreover, improvements in the sensitivity and specificity of imaging as well as the development of new serological assays to detect brain metastases promise to revolutionize IMD diagnosis. In this review, we will explore current treatment principles in patients with IMD, including the emerging role of targeted and immunotherapy in select primary cancers, and discuss potential areas for further investigation.
- Open Access
Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease
Nearly 30% of patients with cancer will develop intracranial metastatic disease (IMD), and more than half of these patients will die within a few months following their diagnosis. In light of the profound effect of IMD on survival and quality of life, there is significant interest in identifying biomarkers that could facilitate the early detection of IMD or identify patients with cancer who are at high IMD risk. In this review, we will highlight early efforts to identify biomarkers of IMD and consider avenues for future investigation.
Open AccessClinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease
Nearly 30% of patients with cancer will develop intracranial metastatic disease (IMD), and more than half of these patients will die within a few months following their diagnosis. In light of the profound effect of IMD on survival and quality of life, there is significant interest in identifying biomarkers that could facilitate the early detection of IMD or identify patients with cancer who are at high IMD risk. In this review, we will highlight early efforts to identify biomarkers of IMD and consider avenues for future investigation.